药物重定位在新药研发中的研究进展

Progress in research on drug repositioning in new drug research and development

针对新药研发的途径主要有两种:一种为从头开始合成,另一种为药物重定位。前者从思路的确定到药物批准上市需要耗费大量的人力物力;而后者是指发现目前已经上市药物的新适应症,它不仅是目前新药研发中风险与效益比较好的手段,还是解决新药研发高投入高风险低回报困境的有效策略。目前,被FDA批准上市的重定位药物已有上百种,针对抗菌药物、抗病毒药物以及抗癌抗肿瘤药等研究也越来越多。本文主要针对药物重定位在新药研发中的研究进展进行阐述,阐明目前关于重定位药物的研究报道以及应用前景。

There are two main approaches to new drug development: one is synthesis from scratch, and the other is drug repositioning. The former requires a lot of manpower and material resources from the determination of ideas to the approval of drugs on the market, while the latter mainly refers to the discovery of new indications of drugs already on the market, which is not only strategy with low risks and high benefits in the current new drug research and development. It is also effective means to solve the dilemma of high investment, high risk and low return in new drug research and development. At present, there are hundreds of drugs that have been successfully repositioned, and more and more researches are being conducted in the fields of antibacterial drugs, antiviral drugs, and anticancer and antitumor drugs. This article focuses on the potential of drug repositioning describes the progress in new drug research and development, and clarifies reports about the relocation of drug research and application prospects.